MyMD Pharmaceuticals, Inc. Banner Image

MyMD Pharmaceuticals, Inc.

  • Ticker MYMD
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
MyMD Pharmaceuticals, Inc. Logo Image
  • 11-50 Employees
  • Based in Baltimore, Maryland
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), is a clinical stage biopharma company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases. MyMD’s lead clinical candidate, MYMD-1®, is an orally available next-generation TNF-α inhibitor with the potential to transform the way that TNF-α based diseases are treated. MYMD-1®, withMore its small molecule design, improved safety profile and ability to cross the blood brain barrier, has the promise to provide meaningful therapeutic solutions to patients not served by current TNF-α inhibitors and as a potential therapy for CNS-based inflammatory and autoimmune diseases. The company has completed Phase 2 studies of MYMD-1® for sarcopenia/frailty, a result of the aging process, as well as early-stage trials for rheumatoid arthritis (RA), with the potential to expand into other applications.
4.8 / 5.0 (268)

MyMD Pharmaceuticals, Inc. reports have an aggregate usefulness score of 4.8 based on 268 reviews.

MyMD Pharmaceuticals, Inc.

Most Recent Annual Report

MyMD Pharmaceuticals, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

MyMD Pharmaceuticals, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!